pharmaphorum

JULY 26, 2021

While there are plenty of tests already available that can give a yes/no reading of whether antibodies are present, the Chembio test measures the level of antibodies as well, so can tell whether a patient is likely to be protected against the coronavirus. The post Rapid COVID immune status test launched in UK, Ireland appeared first on.

Immunization 137

Immunization Vaccines FDA 137

The Checkup by Singlecare

SEPTEMBER 12, 2023

Luckily, there’s a shot to help prevent it: Shingrix, the shingles vaccine. The Shingrix vaccine triggers the immune system to respond to the varicella virus and suppress the outbreak of shingles,” says David Cutler , MD, a family medicine physician at Providence Saint John’s Health Center in Santa Monica, California.

Vaccines 105

Vaccines Immunization Pharmacy Program Director Chemotherapy 105

Pharmacy Times

OCTOBER 3, 2023

In addition to the annual flu vaccines, COVID-19 boosters and RSV vaccines present new opportunities for pharmacists to advise patients.

Immunization 65

Immunization Vaccines 65

Pharmafile

OCTOBER 25, 2023

GSK announced positive results from its phase 3 trial which assessed the immune response and safety of Arexvy, its respiratory syncytial virus (RSV) vaccine, adjuvanted, in adults aged 50 to 59 including those at an increased risk of RSV lower respiratory tract disease (LRTD) due to underlying conditions.

Vaccines 59

Vaccines Immunization 59

European Pharmaceutical Review

APRIL 25, 2023

The R21/Matrix-M malaria vaccine, developed by the University of Oxford , has been approved for use in Ghana (13 April 2023) and was authorised for use in Nigeria on 17 April. How does the R21/Matrix-M vaccine work? This technology has been used successfully in Novavax’s COVID-19 vaccine.

Vaccines 105

Vaccines Immunization FDA 105

Pharmafile

APRIL 3, 2023

aVaxziPen, a biotech company focusing on the development of a novel needle-free vaccine delivery platform, has announced that it will present data at the World Vaccine Congress (WVC) in Washington, US. read more

Vaccines 72

Vaccines Immunization 72

Pharmaceutical Technology

MAY 11, 2023

Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.

Vaccines 138

Vaccines Immunization 138

European Pharmaceutical Review

DECEMBER 15, 2023

Moderna and MSD have announced follow-up data from the Phase IIb clinical trial evaluating cancer vaccine mRNA-4157 (V940) in combination with MSD’s Keytruda in patients with resected high-risk melanoma. Keytruda is an immunotherapy that works by increasing the ability of the body’s immune system to help detect and fight tumour cells.

Vaccines 94

Vaccines Research Laboratories Immunization 94

Pharma Mirror

FEBRUARY 18, 2021

A novel approach for ensuring the virtually unlimited production of QS-21, the ‘Gold Standard’ adjuvant for improving vaccine efficacy, will be the subject of an upcoming presentation at the BIO CEO & Investor Digital Conference, starting February 16.

Immunization 52

Immunization Vaccines 52

European Pharmaceutical Review

MAY 12, 2023

A BioNTech-led Phase I trial demonstrated preliminary evidence that adjuvant autogene cevumeran, a personalised mRNA neoantigen vaccine, in combination with atezolizumab (Genentech) and mFOLFIRINOX can induce substantial T cell activity in pancreatic ductal adenocarcinoma (PDAC). Can an mRNA vaccine stimulate T cell response?

Vaccines 88

Vaccines Immunization Chemotherapy 88

Pharmaceutical Technology

JUNE 6, 2023

Oragenics has secured funding from the Canadian bioresearch consortium CQDM to develop a variant-agnostic protein antigen for use in its Covid-19 intranasal vaccine. In March 2023, Oragenics and Inspirevax entered an exclusive global licence deal to develop the former’s lead intranasal Covid-19 vaccine candidate, NT-CoV2-1.

Vaccines 92

Vaccines Immunization 92

pharmaphorum

SEPTEMBER 27, 2022

Ben Hargreaves finds that the next step to enhance these treatments further could be to find synergies with emerging therapies employing similar modes of action, such as therapeutic cancer vaccines. One area that is becoming more widely discussed with the potential to be added to this group is that of therapeutic cancer vaccines.

Vaccines 97

Vaccines Immunization 97

European Pharmaceutical Review

DECEMBER 2, 2022

Vaccines Europe has unveiled its first pipeline review of its 15 members companies, with 100 vaccine candidates as of July 2022. . The data indicated 46 percent of the vaccine candidates target infections that do not have an available vaccine. Establish digital vaccination registries to improve vaccination coverage rates.

Vaccines 92

Vaccines Immunization 92

pharmaphorum

SEPTEMBER 10, 2020

The programme is still in the early stages of development, but if it works in trials would provide another approach to prevent transmission of SARS-CoV-2, the virus that causes COVID-19, alongside vaccines and prophylactic antibodies. subtilis spores engineered to present SARS-CoV-2 antigens to the mucosal immune system.

Vaccines 133

Vaccines Adverse Reactions Immunization 133

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccines 119

Vaccines Immunization 119

pharmaphorum

AUGUST 25, 2022

Today on the pharmaphorum podcast, Editor in Chief Jonah Comstock welcomes Hedi Ben Brahim and Eric Quéméneur, CEO and chief science officer respectively of Transgene, to discuss cancer vaccines in general and Transgene’s recent work in the space in particular. . Podbean. .

Vaccines 52

Vaccines Immunization 52

Pharmaceutical Technology

OCTOBER 6, 2022

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.

Vaccines 59

Vaccines Immunization 59

Pharmaceutical Technology

AUGUST 15, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional authorisation for Moderna ’s Covid-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron), for use in adults aged 18 years and above. It comprises mRNA-1273 (Spikevax) and a vaccine candidate that acts on the SARS-CoV-2 virus’ BA.1

Vaccines 85

Vaccines Immunization 85

European Pharmaceutical Review

OCTOBER 21, 2022

GSK announced Shingrix (Zoster Vaccine Recombinant, Adjuvanted), the first approved shingles vaccine to combine a non-live antigen with a GSK-made adjuvant, can prevent shingles (herpes zoster) for at least decade. An interim analysis conducted over more than four years of long-term follow-up (LTFU) showed vaccine efficacy was 81.6

Vaccines 84

Vaccines Immunization 84

Pharmaceutical Technology

JUNE 23, 2022

The US Food and Drug Administration (FDA) has granted approval for Merck's (MSD outside the US and Canada) pneumococcal 15-valent conjugate vaccine, Vaxneuvance, for use in children aged six weeks to 17 years. The post US FDA grants approval for Merck’s pneumococcal vaccine for children appeared first on Pharmaceutical Technology.

Vaccines 59

Vaccines FDA Research Laboratories Immunization 59

Pharmafile

APRIL 18, 2023

read more

Immunization 40

Immunization Vaccines 40

pharmaphorum

JANUARY 13, 2021

IO Biotech, an oncology specialist formed and backed by Denmark’s Novo Holdings, has raised €127 million ($155 million) to further develop its cancer vaccine technology that has boosted efficacy of PD-1 immunotherapy in early trials. The post IO Biotech raises $155m to develop breakthrough cancer vaccine appeared first on.

Vaccines 94

Vaccines Immunization Compounding 94

Pharmaceutical Technology

JULY 18, 2022

GlaxoSmithKline (GSK) has signed an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to aid in protecting adults and children in the country. The company intends to supply both vaccines from its 230,000ft² Sainte-Foy facility in Quebec. .

Vaccines 64

Vaccines Immunization 64

European Pharmaceutical Review

OCTOBER 21, 2022

Clinical trial results presented at the US IDWeek conference, revealed a three-dose series of the HEPLISAV-B vaccine prevents hepatitis B virus (HBV) in HIV patients not previously vaccinated against or infected with the virus. It will also evaluate ENGERIX-B, a GSK-manufactured three-dose hepatitis B vaccine series.

Vaccines 71

Vaccines Immunization FDA 71

Pharmaceutical Technology

JUNE 30, 2022

HDT Bio has received Emergency Use Approval from Indian regulators for its Covid-19 vaccine, Gemcovac. The vaccine leverages self-amplifying RNA (saRNA), which can replicate itself after administration and could be effective at very low doses. HDT Bio CEO Steve Reed said: “Our saRNA vaccine is a game-changer.

Vaccines 64

Vaccines Immunization 64

Pharmaceutical Technology

MARCH 31, 2023

The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March.

Vaccines 110

Vaccines Immunization 110

STAT

FEBRUARY 22, 2023

This year’s flu shot generated relatively robust levels of protection, new data show, with the vaccine’s effectiveness ranging between about 45% and 55%, depending on the age group and the metric studied, such as whether there was protection against any infection or infection that was severe enough to require hospitalization.

Immunization 98

Immunization Hospitals Vaccines 98

Pharmaceutical Technology

AUGUST 19, 2022

The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has provided interim policy recommendations for the usage of French company Valneva’s Covid-19 vaccine, VLA2001. According to the recommendations, two 0.5ml intramuscular doses of the vaccine are intended to be given as part of the initial dosing regimen.

Vaccines 52

Vaccines Immunization 52

Hospital Pharmacy Europe

NOVEMBER 24, 2022

A fentanyl vaccine induced significant antibody levels and reduced brain levels of the drug and could be of value in opiate use disorder. The principle is simple: a conjugate vaccine is designed to elicit an immune response to the abused opioid (e.g., Fentanyl vaccine effectiveness. Citation Haile CN et al.

Vaccines 59

Vaccines Immunization Hospitals 59

European Pharmaceutical Review

AUGUST 22, 2022

THE GLOBAL outbreak of the COVID-19 pandemic triggered an urgent need to protect people’s lives and livelihoods and the healthcare community recognised quite early that vaccines were the best solution to this crisis. Novel biotechnology platforms for vaccine development.

Vaccines 85

Vaccines Immunization 85

pharmaphorum

MAY 9, 2022

vaccine to treatment with Roche’s cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer. is an ‘off-the-shelf’ vaccine based on a standardised formulation, but the underlying technology is the same as for VB10.NEO Adding Nykode Therapeutics’ VB10.16

Vaccines 64

Vaccines Immunization 64

PharmaShots

FEBRUARY 28, 2023

The signs and symptoms of a potential vaccine injury can vary. Other adverse reactions that could be attributed to a vaccine injury include neurological disorders such as seizures, autoimmune diseases, and allergic reactions. If these symptoms manifest following vaccination, check with your doctor or a vaccine injury lawyer.

Vaccines 40

Vaccines Adverse Reactions Immunization 40

pharmaphorum

MARCH 30, 2022

CureVac and GlaxoSmithKline’s first attempt to develop a COVID-19 vaccine was a salutary reminder of the pitfalls in drug development, as the mRNA shot crashed and burned in a clinical trial last year, but they aren’t giving up. ” The post CureVac and GSK try again with COVID-19 vaccine appeared first on. .

Vaccines 64

Vaccines Immunization 64

European Pharmaceutical Review

SEPTEMBER 1, 2023

Global mRNA-based oncology therapy market At present, the pharmaceutical industry is still awaiting the first regulatory approval of an mRNA-based oncology therapy. If successful, this trial will mark the first time an mRNA cancer vaccine and an immune checkpoint inhibitor have shown improved recurrence-free survival rates.

Immunization 87

Immunization Vaccines 87

Hospital Pharmacy Europe

NOVEMBER 7, 2022

The mRNA-1273 vaccine has been shown to generate an antibody response in children from 6 months which is non-inferior to that of young adults. However, whether the vaccine remains safe and able to elicit a satisfactory antibody response in children from 6 months of age is uncertain and was the purpose of the present study.

Vaccines 52

Vaccines Immunization Hospitals 52

Pharmaceutical Technology

MAY 26, 2023

was powered by the advent of immune-checkpoint inhibitors, added Chalk. GlobalData separates immuno-oncology treatments into six broad classes, which include bispecific antibodies, cancer vaccines, and cell therapies. Click here to watch this webinar and access the presentation. This high compound annual growth rate of 23.6%

Immunization 105

Immunization Vaccines Compounding Insurance 105

pharmaphorum

AUGUST 10, 2021

BioNTech has suggested that giving booster doses of its current Comirnaty (BNT162b2) COVID-19 vaccine may be a preferable strategy to modifying the Pfizer-partnered shot. “It is quite possible that in the next six months to 12 months further variants emerge and that would require adaptation of the vaccine,” he added.

Vaccines 116

Vaccines Immunization 116